| Date Filed | Type | Description |
| 10/03/2023 |
4
| Espinoza Octavio (CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 346 shares
@ $59.92, valued at
$20.7k
|
|
| 09/27/2023 |
8-K
| Quarterly results |
| 09/26/2023 |
4
| Zimmermann Martine (Director) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 2,285 shares
@ $0
Granted 11,345 options to buy
@ $59.08, valued at
$670.3k
|
|
| 08/14/2023 |
4
| Reardon Andrew (CHIEF LEGAL OFFICER &) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 897 shares
@ $68.73, valued at
$61.7k
|
|
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
4
| Korenberg Matthew E (PRESIDENT & CHIEF OPERATING) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 376 shares
@ $56.78, valued at
$21.3k
|
|
| 07/10/2023 |
4
| Espinoza Octavio (CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 375 shares
@ $56.78, valued at
$21.3k
|
|
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/18/2023 |
4
| KOZARICH JOHN W (Director) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Sold 4,444 shares
@ $77.2009, valued at
$343.1k
|
|
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
4
| KOZARICH JOHN W (Director) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Sold 5,819 shares
@ $76.511, valued at
$445.2k
Sold 589 shares
@ $77.0974, valued at
$45.4k
Exercised 6,408 options to buy
@ $18.82, valued at
$120.6k
|
|
| 05/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/20/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/20/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/27/2023 |
4
| Espinoza Octavio (CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 6,046 shares
@ $0
Granted 16,419 options to buy
@ $75.09, valued at
$1.2M
|
|
| 02/27/2023 |
4
| Korenberg Matthew E (President & COO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 9,069 shares
@ $0
Granted 24,628 options to buy
@ $75.09, valued at
$1.8M
|
|
| 02/27/2023 |
4
| Reardon Andrew (See Remarks) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 5,668 shares
@ $0
Granted 15,393 options to buy
@ $75.09, valued at
$1.2M
|
|
| 02/27/2023 |
4
| Davis Todd C (CEO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 17,005 shares
@ $0
Granted 46,178 options to buy
@ $75.09, valued at
$3.5M
|
|
| 02/22/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13D/A
| LIGAND PHARMACEUTICALS INC reports a 7.9% stake in Viking Therapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC reports a 0.8% stake in Ligand Pharmaceuticals Incorporated |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/04/2023 |
4
| Espinoza Octavio (CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 275 shares
@ $56.78, valued at
$15.6k
|
|
| 12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|